Central blood pressure and nighttime blood pressure in patients with non-diabetic chronic kidney disease by Kuczera, Piotr et al.
34 www.ah.viamedica.pl
ORIGINAL PAPER
Address for correspondence: Prof. Andrzej Więcek
Department of Nephrology, Transplantation and Infernal Medicine 
Medical University of Silesia
Francuska 20/24, 40–027 Katowice
tel.: +48 32 255–26–95; fax: +48 32 255–37–26
e-mail: awiecek@sum.edu.pl
Copyright © 2017 Via Medica, ISSN 2449–6170
Central blood pressure and nighttime blood 
pressure in patients with non-diabetic chronic 
kidney disease
Piotr Kuczera1, Katarzyna Kwiecień1, Marcin Adamczak1, Teresa Bączkowska2, Jolanta Gozdowska2, 
Katarzyna Madziarska3, Hanna Augustyniak-Bartosik3, Beata Czerwieńska1, Marian Klinger3,  
Magdalena Durlik2, Andrzej Więcek1
1Department of Nephrology, Transplantation and Infernal Medicine, Medical University of Silesia, Poland 
2Department of Transplant Medicine and Nephrology, Medical University of Warsaw, Warsaw, Poland 
3Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland
Abstract
Introduction. Arterial hypertension is a well-known risk factor of both cardiovascular complications and faster pro-
gression of chronic kidney disease (CKD). There is growing evidence that central blood pressure (BP) and nighttime 
BP may have an advantage in predicting the risk of cardiovascular complications and the progression of CKD in 
comparison with the traditional office BP measurements. The aim of this study was to evaluate the central BP and 
nighttime BP in non-diabetic CKD patients with no, or only mild proteinuria i.e. autosomal dominant polycystic 
kidney disease (ADPKD) or IgA nephropathy (IgAN).
Material and methods. Forty patients with CKD stage 3 or 4 were enrolled into the study. In each patient the 
measurement of peripheral and central BP was conducted, as well as the assessment of pulse wave velocity (PWV) 
and the 24-hour blood pressure monitoring (ABPM). 
Results. Despite the lower office and central BP values in patients with IgAN in comparison to patients with  
ADPKD, both studied groups did not differ in the mean BP in the 24-hour ABPM. In the entire studied group  
a significant positive correlation was found between the augmentation pressure and age, as well as between the aug-
mentation index - AIx% and age. Moreover, a significant positive correlation between the decrease of nighttime BP 
and eGFR was observed. Additionally, a significant positive correlation between PWV and age was found.
Conclusions.
1. Patients with ADPKD and IgAN, despite the differences in office and central BP do not differ in respect of the 
mean BP in the 24-hour ABPM.
2. In both groups of patients vascular stiffness increases with age and deteriorating kidney function.
3. Lower decrease of nighttime blood pressure is related to the worse kidney function in patients with non-dia-
betic CKD. 
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Background
Arterial hypertension is one of the most aggrava-
ting factors in the development and progression 
of chronic kidney disease (CKD) regardless of its 
etiology. The blood pressure assessment done tra-
ditionally on the brachial artery and has been used 
for over a 100 years for the diagnosis of arterial 
hypertension and monitoring the effects of antihy-
pertensive therapy. 
The elevated values of blood pressure measured 
on the brachial artery (peripheral blood pressure) are 
associated with the increased risk of the development 
of cardiovascular diseases, incidence of stroke and 
development and progression of CKD [1], while the 
decrease of the peripheral blood pressure leads to the 
lower incidence of aforementioned morbidities [2]. 
The results of CAFÉ [3] study seem to suggest 
that the values of blood pressure measured on the 
brachial artery (peripheral blood pressure) not al-
ways correspond to the values of blood pressure in 
the aorta (central blood pressure). However, there is 
continuously more and more evidence, suggesting 
that the central blood pressure — which is the true 
perfusion pressure of the central nervous system, 
heart and kidneys — may differ from the peripheral 
blood pressure because of the effect of blood pres-
sure amplification. This effect is caused by the gra-
dual decrease of the arterial wall elasticity with the 
decrease of the diameter of the arteries. This effect 
may result in the increased central blood pressure 
[4]. The pulse wave generated by the contraction 
of the left ventricle spreads in the arterial branches 
and tends to reflect in the sites of arterial diameter 
reduction (mostly when the muscular type arteries 
turns into the arterioles) and then proceeds upwards 
“back” to the aorta. As a consequence of this phe-
nomenon the shape of pulse wave in the aorta can 
be regarded as a sum of overlapping “primary” pulse 
wave generated by the left ventricle and the “second-
ary” reflected wave returning to the aorta from distal 
parts of the vasculature [5]. 
The central blood pressure increases with the 
higher arterial stiffness which, in turn can be influ-
enced predominantly by the arterial hypertension, 
hyperlipidemia and tobacco use [6, 7]. Moreover the 
central blood pressure rises with age what can be ex-
plained by the more pronounced increase of stiffness 
of the central than peripheral arteries [5, 8].
The results of various clinical and experimental 
studies led to the conclusion that increased arterial 
stiffness is an independent predictor of the risk of all-
-cause mortality [9], cardiovascular mortality [10], as 
well as ischemic heart disease and stroke [11].
As it was already mentioned arterial stiffness tends 
to increase with age, and is sometimes regarded as 
one of the markers of senility. Nevertheless, arterial 
stiffness is also increased in young patients with 
CKD [12, 13]. Moreover, the results of some studies 
shown that arterial stiffness increases across the stages 
of CKD [13–15]. 
As it was mentioned before the central blood pres-
sure and the pulse wave velocity (PWV) — a sur-
rogate of the arterial stiffness are linked to the car-
diovascular risk in the general population as well as 
in patients with hypertension and CKD. However, 
there have been no studies conducted that would 
assess the detailed profile of central blood pressure 
in non-diabetic CKD patients with mild- or no-pro-
teinuria. 
The results of some small clinical studies revealed 
that in patients with CKD nondipping circadian 
blood pressure pattern is common [16]. This is prob-
ably caused by both hypervolemia and increased 
arterial stiffness. Moreover, the non-dipping blood 
pressure profile and increased central blood pressure 
have been described in patients with diabetes and 
diabetic nephropathy i.e. chronic morbidities usually 
characterized by significant proteinuria [17]. It has 
been also postulated that the achievement of normal 
nocturnal blood pressure (e.g. by administering ad-
ditional antihypertensive drugs during the bed time 
at night) could be the most important target of treat-
ment in this group of patients [18]. 
In patients with CKD of non-diabetic etiology the 
less pronounced dipping, or even reversed dipping 
(paradoxical increase of blood pressure during night-
-time) has also been described [19, 20]. However, the 
exact pathomechanism of the abovementioned phe-
nomenon has not been described so far. Also, if the 
nondipping/reversed dipping phenomenon can lead 
to faster progression of CKD has not been unequiv-
ocally confirmed. There is however some data avail-
able, that in fact nondipping can accelerate CKD 
progression [21]. 
Additionally, it is worth to mention that in pa-
tients with essential hypertension the nighttime 
blood pressure seems to be the strongest predictor of 
the occurrence of cardiovascular events. Still, achiev-
ing the target nighttime blood pressure remains one 
of the most difficult obstacles to surpass in the treat-
ment of arterial hypertension [22]. 
It seems then, that the elevated nighttime blood 
pressure in CKD patients with the acceptable blood 
pressure control during the day may have a great 
impact on the target organ damage in the course of 
arterial hypertension. However, there have been no 
studies conducted so far, that would precisely assess 
arterial hypertension 2017, vol. 21, no. 1
36 www.ah.viamedica.pl
the profiles of nighttime blood pressure in CKD pa-
tients with no- or only mild proteinuria. 
The aim of this study was to assess the central 
blood pressure and nighttime blood pressure in 
non-diabetic CKD patients with no- or only mild 
proteinuria i.e. autosomal dominant polycystic kid-
ney disease (ADPKD) and IgA nephropathy (IgAN). 
Material and methods
Forty adult patients with CKD stage 3 or 4 (eGFR 
15.0–59.9 ml/min/1.73 m2) have been enrolled into 
the study. The eGFR was calculated according to the 
MDRD formula. The patients’ mean age was 49.0 ± 
± 14.7 years. The etiology of non-diabetic CKD was 
confirmed during the careful clinical evaluation as 
follows: ADPKD in 30 patients and IgAN based on 
kidney biopsy in 10 patients. 
Patients with severe heart or liver failure with 
expected survival time shorter than 12 months were 
excluded from the study. Moreover, patients with 
significant heart arrhythmias, including atrial fibril-
lation also could not be enrolled, as those types of ar-
rhythmias preclude the accurate pulse wave analysis. 
The study protocol was adherent to the Declaration 
of Helsinki and all patients had given the written 
informed consent for the participation in the study.
In all of the patients a standard blood pressure 
measurement on the left brachial artery after 10 min-
ute rest has been conducted. Patients had their backs 
supported and the brachial artery was at the level of 
the heart. Next the noninvasive central blood pres-
sure and PWV measurements have been done using 
the applanation tonometry using the SphygmoCor 
Device (AtCor Medical Pty Ltd, West Ryde NSW, 
Australia). Central blood pressure measurements 
have been done after a 10 minute rest in a supine 
position. The tonometer was placed on the left radial 
artery in the site that the pulse was best palpable.
Then, the PWV assessment in aorta has been con-
ducted. The tonometer was placed on the common 
carotid (CCA) and femoral arteries, respectively in 
the sites where the pulse was best palpable. In this 
method the time variable of the PWV is calculated 
relatively to the tip of the “R” wave in the ECG that is 
conducted simultaneously. Thus, when the heart rate 
differed more than 5 beats per minute between the 
measurements on the CCA and femoral artery, the 
result was discarded and the measurement repeated. 
Next, the 24-hour ABPM has been conducted 
in all of the enrolled patients using the A&D TM-
-2430 device (A&D Instruments LTD, Abingdon, 
UK). The measurements have been taken every 15 min-
utes during daytime and nighttime. Blood pressure 
values gathered between 6 AM and 10 PM were 
regarded as daytime values and from 10 PM to 6 AM 
as nighttime values. Morning blood pressure surge 
(MBPS) was calculated as a difference between mean 
blood pressure from the 2 hours after awakening and 
the mean from 3 measurements obtained during 
nighttime (the lowest recorded measurement and the 
measurements obtained 15 minutes before and after 
the lowest one). 
The statistical calculations have been done with 
the Statistica 10.0 software (StatSoft Poland, Cra-
cow, Poland). Shapiro-Wilk test was used to test the 
variables distribution, Kruksal-Wallis test was used to 
assess the differences between variables. Correlation 
coefficients were calculated using Spearman’s rank 
correlation. Results are shown as means with 95% 
confidence index (CI) or as median values with inter-
quartile range (IQR) when appropriate. Differences 
were considered significant when p < 0.05.
The study has been supported by the Nation-
al Science Center, contract number: 2011/01/B/ 
/NZ5/00346. 
Results
Patients with ADPKD and IgAN were in a similar 
age (Table I). Mean serum creatinine concentration 
in the whole group of patients was 166 (123–209) 
µmol/L and the eGFR was 47.3 (39.9–54.8) ml/ 
/min/1.73 m2. There were no significant differences 
in the eGFR in the patients with ADPKD and IgAN 
(Table I). The mean body mass index (BMI) in the 
whole group of patients was 25.7 (24.4–26.9) kg/ 
/m2. There was no significant difference in the BMI 
between both studied groups of patients (Table I). 
There was also no significant difference in the num-
ber of antihypertensive medications taken by the 
patients enrolled to both studied groups (Table I).
The mean values of peripheral blood pressure in 
the whole group of patients were: systolic blood pres-
sure (SBP) — 136 (130–142) mmHg; diastolic blood 
pressure (DBP) — 83 (80–87) mmHg. Patients with 
ADPKD had higher peripheral DBP in comparison 
with patients with IgAN. Moreover, a trend (p = 
= 0.07) towards higher peripheral SBP pressure in 
patients with ADPKD has been found. No differenc-
es in pulse pressure (PP) have been found between 
the studied groups (Table II).
The mean values of central blood pressure in the 
whole group of non-diabetic CKD patients were as 
follows: SBP: 128 (122–134) mmHg, DBP: 84 (81– 
–88) mmHg, pulse pressure: 44 (39–48) mmHg, 
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Table I. Clinical characteristics of patients with ADPKD or IgA nephropathy
ADPKD
n = 30
IgAN
n = 10
p
Age (years) 50.6
(44.7–56.4)
47.8
(36.2–59.8)
0.15
BMI [kg/m2] 26.0
(24.6–27.4)
24.6
(21.7–27.4)
0.77
Serum creatinine concentration [µmol/l] 175
(118–233)
132
(100–164)
0.65
eGFR [ml/min/1.73 m2] 43.6
(34.9–52.2)
50.1
(45.0–56.2)
0.49
Number of antihypertensive drugs 2.36 ± 1.37 2.33 ± 1.33 0.97
ADPKD — autosomal polycystic kidney disease; IgAN — IgA nephropathy; BMI — body mass index; eGFR — estimated glomerular filtration rate
Table II. The comparison of the peripheral and central blood 
pressure as well as the pulse wave velocity in patients with  
ADPKD or IgA nephropathy
ADPKD
n = 30
IgAN
n = 10
p
SBP brachial artery
[mmHg]
139
(132–146)
125
(107–142)
0.07
DBP brachial artery
[mmHg]
85
(81–89)
75
(68–82)
0.02
PP brachial artery
[mmHg]
54
(48–60)
50
(35–65)
0.41
SBP central
[mmHg]
130
(124–137)
115
(97–132)
0.03
DBP central
[mmHg]
86
(82–90)
76
(68–83)
0.01
PP central
[mmHg]
44
(39–50)
39
(26–53)
0.30
AP
[mmHg]
15.1
(11.5–18.6)
12.0
(4.5–19.5)
0.38
AIx%
[%]
32.1
(26.1–38.2)
27.6
(18.5–36.6)
0.24
PWV
[m/s]
9.05
(7.86–10.23)
6.68
(2.51–10.90)
0.1
ADPKD — autosomal polycystic kidney disease; IgAN — IgA nephropathy; SBP — systolic blood 
pressure; DBP — diastolic blood pressure; PP — pulse pressure; AP — augmentation pressure; AI% — 
augmentation index; PWV — pulse wave velocity
Table III. The comparison of the 24-hour blood pressure monito-
ring in patients with ADPKD or IgA nephropathy
ADPKD
n = 30
IgAN
n = 10
p
SBP daytime
[mmHg]
140
(134–146)
141
(126–155)
0.86
DBP daytime
[mmHg]
89
(86–92)
83
(72–94)
0.1
SBP nighttime
[mmHg]
119
(111–128)
125
(111–139)
0.34
DBP nighttime
[mmHg]
72
(68–76)
70
(60–80)
0.5
Nighttime SBP decrease
[mmHg]
16
(13–19)
11
(6–16)
0.11
Nighttime DBP decrease
[mmHg]
19
(16–22)
16
(9–23)
0.43
MBPS
[mmHg]
29.3
(20.1–37.8)
19.5
(from –18.1 
to –57)
0.4
Heart rate
[beats/minute]
71
(67–75)
68
(63–72)
0.053
ADPKD — autosomal polycystic kidney disease; IgAN — IgA nephropathy; SBP — systolic blood 
pressure; DBP — diastolic blood pressure; MBPS — morning blood pressure surge
augmentation pressure (AP) 15.0 (11.9–18.1) 
mmHg, augmentation index (AIx%) 31.3 (26.4–
36.2) %. 
Patients with ADPKD were characterized by high-
er values of central SBP and DBP (Table II). No 
differences in the PP, nor the central blood pressure 
parameters (AP, AIx%) have been found between the 
two groups (Table II). 
In the 24-hour ABPM analysis the mean SBP in 
the whole group was: 139 (134–145) mmHg, while 
DBP was: 88 (85–91) mmHg. During nighttime the 
values were: 120 (112–126) mmHg and 73 (69–77), 
respectively. 
The mean dipping values in the whole studied 
group were: SBP 14.5 (11.4–17.6) mmHg, and DBP 
17 (13.8–20.2) mmHg. The dipping exceeding 10% 
occurred in 52% of patients regarding SBP and 72% 
of patients regarding DBP. The mean morning blood 
pressure surge — MBPS was 22 (21–36) mmHg. 
There was a trend (p = 0.053) towards a lower 
heart rate in the patients with IgAN comparing to 
the patients with ADPKD. There were no other sig-
nificant differences regarding ABPM values in both 
studied groups (Table III). 
Correlation analysis
A significant positive correlations between the pa-
rameters of central blood pressure: AP; AIx% and 
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Figure 1. The correlation between the pulse wave velocity and the patients’ age
age were found — R = 0.47; p = 0.004 i R = 0.52; 
p = 0.002, respectively. 
In the whole studied group a significant positive 
correlation (R = 0.39; p = 0.03) between the PWV 
and age was found (Fig. 1). Additionally, a significant 
negative correlation (R = –0.42; p = 0.03) between 
the diastolic nighttime blood pressure decrease and 
PWV was observed. 
Moreover, there has been a significant positive 
correlation found between the decrease of nighttime 
blood pressure and eGFR. The correlation coeffi-
cients for SBP and DBP were: R = 0.49; p = 0.018 
and R = 0.42; p = 0.04, respectively (Fig. 2A, B). 
Discussion
The aim of the present study was to assess the cen-
tral blood pressure and nighttime blood pressure 
in non-diabetic stage 3 and 4 CKD patients. Only 
patients with CKD caused by ADPKD or IgAN and 
no- or low proteinuria were enrolled into this study. 
There were no significant differences in the age, 
excretory kidney function, nor the BMI between 
both studied groups of patients (ADPKD and IgAN 
respectively, Table I). 
 Patients with IgAN were characterized by lower 
office peripheral blood pressure than patients with 
ADPKD (Table II). Interestingly, these differences 
have not been confirmed in the 24-hour ABPM. It 
would be interesting to assume that this difference 
could be due to the described increased sympathetic 
nervous activity in ADPKD patients [23]. This could 
result in a more pronounced “white coat” effect in 
patients with ADPKD, but so far it is only a vague 
hypothesis, which needs confirmation in a larger 
group of patients. Nevertheless, there was a trend 
(p = 0.053) towards a slower mean heart rate in 
patients IgAN in comparison with patients with AD-
PKD, what might be regarded as a rough surrogate 
of the sympathetic nervous activity. The fact that the 
patients did not differ in the number of prescribed 
antihypertensive drugs (Table I) also seems to some-
how strengthen this hypothesis.
Regarding the central blood pressure parameters, 
similarly to the peripheral blood pressure, patients 
with IgAN had lower values of central SBP and 
DBP. It should be noted, however, that there were 
no significant changes in the central blood pressure 
parameters — AP and AIx% were similar in both 
groups (Table II). 
As it was mentioned above, there were no signifi-
cant differences between the values of blood pressure 
during daytime and nighttime in the 24-hour blood 
pressure monitoring, despite the differences in office 
blood pressure values. This has again confirmed the 
low accuracy of office blood pressure measurements 
in patients with CKD.
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Figure 2. The correlation between the eGFR and the decrease of systolic nighttime blood pressure (A) and diastolic nighttime blood pressure (B)
Interestingly, the majority of our patients had 
lower mean blood pressure values during the night 
(dipping) what stays in contrast to some studies con-
ducted before [17, 24]. This might, however, be 
a surrogate of careful antihypertensive treatment in 
patients under a nephrological supervision, as it was 
shown that the appropriate dosing of antihyperten-
sive medication may change the dipping patterns and 
reduce the cardiovascular risk [25].
In the correlation analyses a significant positive 
correlation was found between the parameters of 
central blood pressure and the patients’ age. This is 
in agreement with some other clinical studies con-
ducted so far in patients with essential hypertension 
as well as in general population [5, 6]. 
Interestingly, a significant correlation between the 
nighttime blood pressure decrease and the deterio-
ration of kidney function (positive correlation with 
arterial hypertension 2017, vol. 21, no. 1
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eGFR, negative with serum creatinine concentra-
tion — Fig. 2) was found. These results are also 
in concordance with the clinical studies conducted 
previously [19, 20]. It needs to be underlined that 
the nondipping blood pressure pattern is a strong 
independent risk factor of both cardiovascular and 
general mortality [26].
What is more, a significant positive correlation 
between the PWV and the patients’ age was found 
(Fig. 1). This seems to suggest the increase of arterial 
stiffness with age in patients with CKD stage 3 or 4. 
In this manner, this population of patients resembles 
the general population and patients with terminal 
renal failure [27].
Moreover, a significant negative correlation between 
the diastolic dipping blood pressure pattern and PWV 
was found. This would seem to suggest that the lesser 
diastolic dipping is related to the more pronounced 
stiffness of aorta. This is important in the context 
of the fact that both PWV and the nighttime blood 
pressure are recognized non-classical risk factors of 
cardiovascular complications in this group of patients. 
In conclusion the results of our study suggest 
that patients with ADPKD and IgAN, despite the 
differences in office and central BP, do not differ 
in respect of the mean values of BP in the 24-hour 
ABPM. Additionally, in both groups of patients vas-
cular stiffness increases with age and deteriorating 
kidney function. Finally, lower decrease of nighttime 
blood pressure is related to the worse kidney function 
in patients with non-diabetic CKD.
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